Thibault Vandhuick1, Yannick Allanore2, Didier Borderie2, Jean-Pierre Louvel3, Patrice Fardellone4, Philippe Dieudé5, Vincent Goëb4, Gaëlle Clavel6, Marie Christophe Boissier7, Fabienne Jouen8, Patrick Boumier4, Jean-Dominique Allart9, Othmane Mejjad10, Sophie Pouplin10, Mary Jan11, Jean François Ménard11, Xavier Le Loët1, Olivier Vittecoq12. 1. Rheumatology Department, CIC/CRB1404, Rouen University Hospital, and Inserm Unit 905, IRIB, Rouen University, Rouen, France. 2. Paris Descartes University, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France. 3. Radiology Department, Rouen University Hospital, Rouen, France. 4. Rheumatology Department, Amiens University Hospital, Amiens, France. 5. Paris Diderot University, Bichat Claude-Bernard Hospital, Assistance Publique des Hôpitaux de Paris, France. 6. INSERM UMR 1125 and Rheumatology Department, CHU Avicenne (APHP), Bobigny; and Department of Internal Medicine, Fondation A. De Rothschild, Paris, France. 7. INSERM UMR 1125 and Rheumatology Department, CHU Avicenne (APHP), Bobigny, France. 8. Inserm Unit 905, IRIB, Rouen University, Rouen, France. 9. Radiology Department, Pauchet Hospital, Amiens, France. 10. Rheumatology Department, Rouen University Hospital, Rouen, France. 11. Biostatistics Department, Rouen University Hospital, Rouen, France. 12. Rheumatology Department, CIC/CRB1404, Rouen University Hospital, and Inserm Unit 905, IRIB, Rouen University, Rouen, France. olivier.vittecoq@chu-rouen.fr.
Abstract
OBJECTIVES: Accelerated atherosclerosis has emerged as a critical issue in rheumatoid arthritis (RA). There is a need to better understand the link between RA and atherosclerosis. Our aim was to identify parameters associated with the development of subclinical atheroma in a very early arthritis (VErA) cohort. METHODS: VErA-cohort patients were prospectively recruited from 1998 to 2002. Arthritis treatment was standardised from onset. The clinical, biological and radiological parameters of all patients were collected from inclusion. Carotid intima-media thickness (cIMT) was measured 7 years after their first symptoms. RESULTS: Among 105 patients included, 82 developed RA (mean age at onset: 51.7±12.8 years). Mean carotid artery IMT at year 7 was 0.67±0.12 mm. Larger thickness defined by values above the median (0.66) was associated with inclusion age (p<10-6), swollen joint count (p=0.01), DAS44 (p=0.048) and hypertension (p=0.006). In contrast, anti-CCP positivity (>50 UA/ml) was associated with thinner cIMT (p=0.03). Baseline as well as cumulated values of markers reflecting systemic inflammation, lymphocyte activation, endothelial dysfunction and oxidative stress were not correlated with carotid subclinical atherosclerosis. Major independent atheroma risk factors retained by multivariate analyses were hypertension (OR 4.33 [1.59-11.73]; p=0.004) and swollen joint count at inclusion (OR 3.87 [1.54-9.72]; p=0.004), while methotrexate use was a protective marker (OR 0.27 [0.11-0.71]; p=0.007). CONCLUSIONS: This study conducted from the VErA vascular cohort of community-cases of RA confirm that cIMT is under the influence of classical CV risk (hypertension), disease marker (SJC) and methotrexate intake.
OBJECTIVES: Accelerated atherosclerosis has emerged as a critical issue in rheumatoid arthritis (RA). There is a need to better understand the link between RA and atherosclerosis. Our aim was to identify parameters associated with the development of subclinical atheroma in a very early arthritis (VErA) cohort. METHODS: VErA-cohort patients were prospectively recruited from 1998 to 2002. Arthritis treatment was standardised from onset. The clinical, biological and radiological parameters of all patients were collected from inclusion. Carotid intima-media thickness (cIMT) was measured 7 years after their first symptoms. RESULTS: Among 105 patients included, 82 developed RA (mean age at onset: 51.7±12.8 years). Mean carotid artery IMT at year 7 was 0.67±0.12 mm. Larger thickness defined by values above the median (0.66) was associated with inclusion age (p<10-6), swollen joint count (p=0.01), DAS44 (p=0.048) and hypertension (p=0.006). In contrast, anti-CCP positivity (>50 UA/ml) was associated with thinner cIMT (p=0.03). Baseline as well as cumulated values of markers reflecting systemic inflammation, lymphocyte activation, endothelial dysfunction and oxidative stress were not correlated with carotid subclinical atherosclerosis. Major independent atheroma risk factors retained by multivariate analyses were hypertension (OR 4.33 [1.59-11.73]; p=0.004) and swollen joint count at inclusion (OR 3.87 [1.54-9.72]; p=0.004), while methotrexate use was a protective marker (OR 0.27 [0.11-0.71]; p=0.007). CONCLUSIONS: This study conducted from the VErA vascular cohort of community-cases of RA confirm that cIMT is under the influence of classical CV risk (hypertension), disease marker (SJC) and methotrexate intake.
Authors: F Verhoeven; P Totoson; K Maguin-Gaté; A Prigent-Tessier; C Marie; D Wendling; J Moretto; C Prati; C Demougeot Journal: Clin Exp Immunol Date: 2017-03-09 Impact factor: 4.330
Authors: Elaine Cristina Faria Abrahão-Machado; José Alexandre Mendonça; Ana Carolina Belini Bazán Arruda; Luciana Bertoldi Nucci; Marcel Alex Soares Dos Santos Journal: An Bras Dermatol Date: 2020-01-31 Impact factor: 1.896
Authors: Anna Raczkiewicz; Aleksandra Juszkiewicz; Bartłomiej Kisiel; Artur Bachta; Joanna Kur-Zalewska; Krzysztof Kłos; Olga Bujakowska; Małgorzata Tłustochowicz; Witold Tłustochowicz Journal: Arch Med Sci Atheroscler Dis Date: 2016-05-30